aTyr Pharma
ATYRPhase 2aTyr Pharma is translating the biology of tRNA synthetases, essential enzymes with newly discovered extracellular signaling functions, into first-in-class medicines for fibrosis and inflammation. The company's lead asset, efzofitimod, has demonstrated proof-of-concept in pulmonary sarcoidosis and is being advanced in a pivotal Phase 3 trial, with a parallel Phase 2 program in SSc-ILD. Through its subsidiary Pangu BioPharma in Hong Kong, aTyr is also exploring bispecific antibodies targeting Neuropilin-2 (NRP2) in oncology, expanding its platform's therapeutic reach.
ATYR · Stock Price
Historical price data
AI Company Overview
aTyr Pharma is translating the biology of tRNA synthetases, essential enzymes with newly discovered extracellular signaling functions, into first-in-class medicines for fibrosis and inflammation. The company's lead asset, efzofitimod, has demonstrated proof-of-concept in pulmonary sarcoidosis and is being advanced in a pivotal Phase 3 trial, with a parallel Phase 2 program in SSc-ILD. Through its subsidiary Pangu BioPharma in Hong Kong, aTyr is also exploring bispecific antibodies targeting Neuropilin-2 (NRP2) in oncology, expanding its platform's therapeutic reach.
Technology Platform
Platform based on extracellular tRNA synthetase biology, leveraging naturally occurring immunomodulatory protein fragments to develop therapies for inflammation and fibrosis.
Pipeline
8| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Efzofitimod 1 mg/kg + Efzofitimod 3 mg/kg + Placebo | SARS-CoV-2 (COVID-19) Severe Pneumonia | Phase 2 | |
| efzofitimod 450 mg + efzofitimod 270 mg + Placebo | Interstitial Lung Disease | Phase 2 | |
| Efzofitimod 1.0 mg/kg or Placebo + Efzofitimod 3.0 mg/kg or ... | Pulmonary Sarcoidosis | Phase 1/2 | |
| ATYR1940 | Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 1/2 | |
| Placebo + ATYR1940 | Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 1/2 |
Funding History
5Opportunities
Risk Factors
Competitive Landscape
In pulmonary sarcoidosis, competes against generic corticosteroids and immunosuppressants; key differentiation is targeted mechanism and steroid-sparing potential. In SSc-ILD, faces competition from approved therapies nintedanib and tocilizumab. The Pangu oncology program would enter a crowded bispecific antibody field but with a novel target in NRP2.